Guselkumab, administered every 4 or 8 weeks, is effective and safe in patients with active psoriatic arthritis who have had an inadequate response to only one prior TNF inhibitor.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/guselkumab-effective-after-tnf-inhibitor-failure-patients-2026a10007tm?src=rss
Author :
Publish date : 2026-03-13 13:11:00
Copyright for syndicated content belongs to the linked Source.
